If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,548.00    -6.00 (-0.39%)
Bid:
1,544.00
Ask:
1,547.00
Spread: 3.00 (0.194%)
Market Cap: £3.26b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Annual Information Update

2 Aug 2010 12:16

RNS Number : 3618Q
Hikma Pharmaceuticals Plc
02 August 2010
 



 

 

Annual Information Update

LONDON, 2 August 2010. In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ("Hikma" or "the Company") (LSE: HIK) sets out below a summary of the information which has been published or made available to the public over the period. The information referred to in this Update was up to date at the time the information was published, but some information may now be out of date.

Stock Exchange Announcements

Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the Company's market news section on the London Stock Exchange website at (http://www.londonstockexchange.com/prices-and-news/stocks/stocks-and-prices.htm) or from the press releases page on the Company's website at (http://www.hikma.com/investorrelations/rns/). The Stock Exchange announcements made during the period were:

Date of Announcement

Headline of Announcement

14 May 2009

Interim Management Statement

14 May 2009

Result of AGM

19 May 2009

Director/PDMR Shareholding

29 June 2009

Director/PDMR Shareholding

5 August 2009

Total Voting Rights

27 August 2009

Half Yearly Report

1 October 2009

Total Voting Rights

1 October 2009

Additional Listing

16 October 2009

Director/PDMR Shareholding

20 October 2009

Blocklisting Interim Review

2 November 2009

Total Voting Rights

12 November 2009

Interim Management Statement

18 November 2009

Director/PDMR Shareholding

18 November 2009

Director/PDMR Shareholding

19 November 2009

Director/PDMR Shareholding

1 December 2009

Director/PDMR Shareholding

1 December 2009

Total Voting Rights

18 December 2009

Director/PDMR Shareholding

4 January 2010

Total Voting Rights

5 January 2010

Director/PDMR Shareholding

1 February 2010

Total Voting Rights

1 March 2010

Notice of Results

10 March 2010

Total Voting Rights

15 March 2010

Blocklisting of Shares

17 March 2010

Preliminary Announcement for 2009

23 March 2010

Director/PDMR Shareholding

30 March 2010

Hikma expands in the Tunisian market

1 April 2010

Blocklisting Six Monthly return

1 April 2010

Voting Rights & Capital

7 April 2010

Director/PDMR Shareholding

8 April 2010

Director/PDMR Shareholding

9 April 2010

Director/PDMR Shareholding

9 April 2010

Director/PDMR Shareholding

9 April 2010

Annual Financial Report

12 April 2010

Hikma expands in the Algerian market

20 April 2010

Director/PDMR Shareholding

23 April 2010

Director/PDMR Shareholding

5 May 2010

Voting Rights & Capital

13 May 2010

Interim Management Statement

13 May 2010

AGM Statement

26 July 2010

Voting Rights and Capital

All of the above announcements were also made by the Company via the NasdaqDubai stock exchange CANDI system. These announcements may be viewed and downloaded from the NasdaqDubai website (www.candi.nasdaq.com).

 

Documents filed with the Financial Services Authority

The Company has filed the following documents with the Financial Services Authority ("FSA") over the previous 12 months. These documents are available to be viewed via the UKLA's Document Viewing Facility at the Financial Services Authority, 25 the North Colonnade, London, E14 5HS or at the Company's registered office.

Date

Document

9 April 2010

Annual Report and Accounts 2009

9 April 2010

Notice of 2010 Annual General Meeting

9 April 2010

Proxy forms for the 2010 Annual General Meeting

9 April 2010

Sterling and Jordanian Dinar dividend election forms

Documents filed with Companies House

The Company submitted filings to the Registrar of Companies in England and Wales as detailed in the table below.

Date Filed

Form

Description

30 July 2010

SH01

31/05/10 statement of capital GBP 19326339

30 July 2010

SH01

30/04/10 statement of capital GBP 19313279

23 July 2010

SH01

31/03/10 statement of capital GBP 19260000

9 June 2010

AA

Group of companies' accounts made up to 31/12/09

8 June 2010

RES01

Alteration to memorandum and articles

8 June 2010

RES10

Authorised allotment of shares and debentures

8 June 2010

RES09

Authority to purchase shares other than from capital

8 June 2010

RES11

Disapplication of pre-emption rights

26 May 2010

RES10

Authorised allotment of shares and debentures

26 May 2010

RES01

Alteration to memorandum and articles

26 May 2010

RES11

Disapplication of pre-emption rights

19 April 2010

SH01

31/01/10 statement of capital GBP 19176400

19 April 2010

SH01

30/11/09 statement of capital GBP 19156490

19 April 2010

SH01

31/12/09 statement of capital GBP 19162760

16 April 2010

SH01

31/03/10 statement of capital GBP 19260000

15 October 2009

AD03

Register(s) moved to sail address

15 October 2009

AD02

Sail address created

29 September 2009

363a

Return made up to 08/09/09; bulk list available separately

24 September 2009

88(2)

AD 01/07/09-30/07/09 issued share capital GBP IC 18982880/18983480

24 September 2009

88(2)

AD 01/06/09-30/06/09 issued share capital GBP IC 18959440/18982880

24 September 2009

88(2)

AD 01/05/09-30/05/09 issued share capital GBP IC 18940080/18959440

24 September 2009

88(2)

AD 01/04/09-30/04/09 issued share capital GBP IC 18912440/18940080

24 September 2009

88(2)

AD 01/03/09 to 30/03/09 issued share capital GBP IC 18888160/18912440

25 July 2009

AA

Group of companies' accounts made up to 31/12/08

3 June 2009

RES10

Authorised allotment of shares and debentures

3 June 2009

RES13

Approve remuneration committee report 14/05/2009

3 June 2009

RES09

Authority to purchase shares other than from capital

3 June 2009

RES11

Disapplication of pre-emption rights

Copies of all these documents may be obtained from Companies House, Crown Way, Maindy, Cardiff CF14 3UZ or, if you are a registered user, they may be viewed and downloaded using Companies House Direct at www.direct.companieshouse.gov.uk.

Further Information

Further information about Hikma Pharmaceuticals PLC can be found at our website www.hikma.com. Copies of all documents can be obtained from the Company at the registered office which is located at 13 Hanover Square, London W1S 1HW.

 

Henry Knowles Company Secretary 2 August 2010

- ENDS -

 

 

Enquiries:

 

Hikma Pharmaceuticals PLC

Henry Knowles

Company Secretary

 

+44 20 7399 2670

Susan Ringdal

Investor Relations Director

 

+44 20 7399 2670

 

Financial Dynamics

Ben Atwell/ Julia Phillips

+44 20 7269 7242

 Jonathan Birt/ Matthew Cole

 

 

 

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2009, Hikma achieved revenues of $637 million and profit attributable to shareholders of $78 million. For news and other information, please visit www.hikma.com.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AIUFLLFBBVFFBBE
Date   Source Headline
9th Mar 20225:53 pmRNSTransaction in Own Shares
8th Mar 20225:21 pmRNSTransaction in Own Shares
8th Mar 202210:21 amRNSHolding(s) in Company
7th Mar 20225:12 pmRNSTransaction in Own Shares
7th Mar 20221:36 pmRNSDirector/PDMR Shareholding
4th Mar 20226:20 pmRNSTransaction in Own Shares
3rd Mar 20225:44 pmRNSTransaction in Own Shares
3rd Mar 20222:44 pmRNSDirector/PDMR Shareholding
2nd Mar 20226:18 pmRNSTransaction in Own Shares
1st Mar 20225:57 pmRNSTransaction in Own Shares
28th Feb 20226:37 pmRNSTransaction in Own Shares
28th Feb 20225:16 pmRNSDirector/PDMR Shareholding
25th Feb 20225:58 pmRNSHikma Share Buyback Programme
25th Feb 20229:37 amRNSDirector/PDMR Shareholding
25th Feb 20227:00 amRNSShare Buyback Programme
24th Feb 20227:00 amRNSDirectorate Change
24th Feb 20227:00 amRNSFinal Results
23rd Feb 20229:23 amRNSHolding(s) in Company
16th Feb 202211:26 amRNSDirector/PDMR Shareholding
11th Feb 202210:17 amRNSHolding(s) in Company
8th Feb 202210:17 amRNSNotice of Results
3rd Feb 20227:00 amRNSHikma completes acquisition of Teligent
2nd Feb 202210:04 amRNSTotal Voting Rights
24th Jan 202212:45 pmRNSHolding(s) in Company
17th Jan 20227:00 amRNSAcquisition
12th Jan 20223:22 pmRNSHolding(s) in Company
10th Jan 20227:00 amRNSHikma Launches 503B Sterile Compounding Business
4th Jan 20222:55 pmRNSTotal Voting Rights
16th Dec 20211:42 pmRNSHolding(s) in Company
14th Dec 20212:34 pmRNSHolding(s) in Company
9th Dec 20217:00 amRNSRichter and Hikma sign agreement for denosumab
2nd Dec 202110:33 amRNSHolding(s) in Company
23rd Nov 20219:57 amRNSHolding(s) in Company
17th Nov 202110:35 amRNSHolding(s) in Company
4th Nov 20217:00 amRNSTrading Statement
1st Nov 20212:06 pmRNSTotal Voting Rights
4th Oct 20219:55 amRNSBlock listing Interim Review
27th Sep 20217:00 amRNSHikma acquires Custopharm
23rd Sep 20217:30 amRNSAdditional Listing
27th Aug 202112:15 pmRNSBio-Thera and Hikma announce exclusive agreement
6th Aug 20217:00 amRNSHalf-year Report
2nd Aug 20212:48 pmRNSTotal Voting Rights
19th Jul 20219:27 amRNSNotice of Results
5th Jul 20213:43 pmRNSTotal Voting Rights
2nd Jun 20211:14 pmRNSTotal Voting Rights
17th May 20214:00 pmRNSDirector/PDMR Shareholding
30th Apr 20217:00 amRNSHikma announces US FDA approval of KLOXXADO
30th Apr 20217:00 amRNSTrading Statement
26th Apr 202111:19 amRNSHolding(s) in Company
23rd Apr 20213:51 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.